MovDisordV3, PascalFrancis, Curation, bibRecord, 000919

Botulinum toxin B reduces sialorrhea in parkinsonism

Identifieur interne : 000919 ( PascalFrancis/Curation ); précédent : 000918; suivant : 000920

Botulinum toxin B reduces sialorrhea in parkinsonism

Auteurs : Brad A. Racette [États-Unis] ; Laura Good [États-Unis] ; Sandy Sagitto [États-Unis] ; Joel S. Perlmutter [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:04-0052651

Descripteurs français

Pascal (Inist)
- Parkinsonisme, Sialorrhée, Toxine, Botulisme, Chimiothérapie, Spasmolytique, Traitement, Complication, Pronostic, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Antispasmodic agent, Botulism, Chemotherapy, Complication, Parkinsonism, Prognosis, Sialorrhea, Toxin, Treatment.

Abstract

We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Botulinum toxin B reduces sialorrhea in parkinsonism`
A11	`01`	`1`		`@1 RACETTE (Brad A.)`
A11	`02`	`1`		`@1 GOOD (Laura)`
A11	`03`	`1`		`@1 SAGITTO (Sandy)`
A11	`04`	`1`		`@1 PERLMUTTER (Joel S.)`
A14	`01`			`@1 Department of Neurology and Neurological Surgery, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`03`			`@1 Department of Anatomy and Neurobiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 4 aut.`
A14	`04`			`@1 USA (Neurology), Washington University School of Medicine @2 St. Louis, Missouri @3 USA`
A14	`05`			`@1 Huntington Disease Society of America Center of Excellence Mallinckrodt Institute of Radiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA`
A20				`@1 1059-1061`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000113072050160`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 04-0052651`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism.
C02	`01`	`X`		`@0 002B02B11`
C03	`01`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Sialorrhée @5 04`
C03	`02`	`X`	`ENG`	`@0 Sialorrhea @5 04`
C03	`02`	`X`	`SPA`	`@0 Sialorrea @5 04`
C03	`03`	`X`	`FRE`	`@0 Toxine @5 07`
C03	`03`	`X`	`ENG`	`@0 Toxin @5 07`
C03	`03`	`X`	`SPA`	`@0 Toxina @5 07`
C03	`04`	`X`	`FRE`	`@0 Botulisme @5 08`
C03	`04`	`X`	`ENG`	`@0 Botulism @5 08`
C03	`04`	`X`	`SPA`	`@0 Botulismo @5 08`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 09`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 09`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 09`
C03	`06`	`X`	`FRE`	`@0 Spasmolytique @5 10`
C03	`06`	`X`	`ENG`	`@0 Antispasmodic agent @5 10`
C03	`06`	`X`	`SPA`	`@0 Espasmolítico @5 10`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`08`	`X`	`FRE`	`@0 Complication @5 18`
C03	`08`	`X`	`ENG`	`@0 Complication @5 18`
C03	`08`	`X`	`SPA`	`@0 Complicación @5 18`
C03	`09`	`X`	`FRE`	`@0 Pronostic @5 19`
C03	`09`	`X`	`ENG`	`@0 Prognosis @5 19`
C03	`09`	`X`	`SPA`	`@0 Pronóstico @5 19`
C03	`10`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`10`	`X`	`ENG`	`@0 Adult @5 20`
C03	`10`	`X`	`SPA`	`@0 Adulto @5 20`
C07	`01`	`X`	`FRE`	`@0 Bactériose @2 NM`
C07	`01`	`X`	`ENG`	`@0 Bacteriosis @2 NM`
C07	`01`	`X`	`SPA`	`@0 Bacteriosis @2 NM`
C07	`02`	`X`	`FRE`	`@0 Infection @2 NM`
C07	`02`	`X`	`ENG`	`@0 Infection @2 NM`
C07	`02`	`X`	`SPA`	`@0 Infección @2 NM`
C07	`03`	`X`	`FRE`	`@0 Homme`
C07	`03`	`X`	`ENG`	`@0 Human`
C07	`03`	`X`	`SPA`	`@0 Hombre`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`05`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`05`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`05`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`06`	`X`	`FRE`	`@0 Glande salivaire pathologie @5 45`
C07	`06`	`X`	`ENG`	`@0 Salivary gland disease @5 45`
C07	`06`	`X`	`SPA`	`@0 Glándula salival patología @5 45`
C07	`07`	`X`	`FRE`	`@0 Stomatologie @5 46`
C07	`07`	`X`	`ENG`	`@0 Stomatology @5 46`
C07	`07`	`X`	`SPA`	`@0 Estomatología @5 46`
C07	`08`	`X`	`FRE`	`@0 ORL pathologie @5 47`
C07	`08`	`X`	`ENG`	`@0 ENT disease @5 47`
C07	`08`	`X`	`SPA`	`@0 ORL patología @5 47`
N21				`@1 033`
N82				`@1 PSI`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002402

Links to Exploration step

Pascal:04-0052651

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Botulinum toxin B reduces sialorrhea in parkinsonism</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>USA (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Huntington Disease Society of America Center of Excellence Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Good, Laura" sort="Good, Laura" uniqKey="Good L" first="Laura" last="Good">Laura Good</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sagitto, Sandy" sort="Sagitto, Sandy" uniqKey="Sagitto S" first="Sandy" last="Sagitto">Sandy Sagitto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0052651</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0052651 INIST</idno>
<idno type="RBID">Pascal:04-0052651</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002402</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000919</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Botulinum toxin B reduces sialorrhea in parkinsonism</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>USA (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Huntington Disease Society of America Center of Excellence Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Good, Laura" sort="Good, Laura" uniqKey="Good L" first="Laura" last="Good">Laura Good</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Sagitto, Sandy" sort="Sagitto, Sandy" uniqKey="Sagitto S" first="Sandy" last="Sagitto">Sandy Sagitto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antispasmodic agent</term>
<term>Botulism</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Parkinsonism</term>
<term>Prognosis</term>
<term>Sialorrhea</term>
<term>Toxin</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Sialorrhée</term>
<term>Toxine</term>
<term>Botulisme</term>
<term>Chimiothérapie</term>
<term>Spasmolytique</term>
<term>Traitement</term>
<term>Complication</term>
<term>Pronostic</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Botulinum toxin B reduces sialorrhea in parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RACETTE (Brad A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GOOD (Laura)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SAGITTO (Sandy)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>PERLMUTTER (Joel S.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology and Neurological Surgery, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>USA (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="05"><s1>Huntington Disease Society of America Center of Excellence Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
</fA14>
<fA20><s1>1059-1061</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113072050160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0052651</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We report on our open-label experience with botulinum toxin B for the treatment of severe sialorrhea associated with parkinsonism. Nine adult patients with parkinsonism and medically intractable sialorrhea were treated with botulinum toxin B (1,000 units into each parotid gland using superficial landmarks). After treatment, patients experienced a 61% mean subjective improvement and a 42% mean reduction of quantitative saliva production. There were no adverse effects seen in any subjects. Mean peak benefit from injections lasted 14 weeks. We conclude that denervation of salivary glands with botulinum toxin B produces excellent reduction of excessive salivation associated with parkinsonism.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B11</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Sialorrhée</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Sialorrhea</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sialorrea</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Toxine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Toxin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Toxina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Botulisme</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Botulism</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Botulismo</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Spasmolytique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antispasmodic agent</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Espasmolítico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Complication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Complication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Complicación</s0>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Bactériose</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Bacteriosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Bacteriosis</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Glande salivaire pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Salivary gland disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Glándula salival patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Stomatologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Stomatology</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Estomatología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>ORL pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>ENT disease</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>ORL patología</s0>
<s5>47</s5>
</fC07>
<fN21><s1>033</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000919 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000919 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0052651
   |texte=   Botulinum toxin B reduces sialorrhea in parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Botulinum toxin B reduces sialorrhea in parkinsonism

Botulinum toxin B reduces sialorrhea in parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri